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Abstract
Background: TGF-b plays a dual role in the progression of human cancer. During the early stages of carcinogenesis, TGF-b
functions as a tumor suppressor. During the late stages of tumor development, however, TGF-b can promote tumor growth
and metastasis. A shift in Smad2/3 phosphorylation from the carboxy terminus to linker sites is a key event determining
biological function of TGF-b in colorectal and hepatocellular carcinoma. In the present study, we investigated the potential
role of differential Smad2/3 phosphorylation in gastric adenocarcinoma.
Methodology: Immunohistochemical staining with anti-P-Smad2/3C and P-Smad2/3L antibodies was performed on 130
paraffin-embedded gastric adenocarcinoma specimens. The relationship between P-Smad2/3C and P-Smad2/3L
immunohistochemical score and clinicopathologic characteristics of patients was analyzed. Real time PCR was used to
measure mRNA expression of Smad2 and Smad3 in cancer and surrounding non-tumor tissue.
Principal Findings: No significant P-Smad2L and/or P-Smad3L positive staining was detected in the majority of specimens
(positive staining in 18/130 samples). Positive P-Smad2/3L staining was not associated with a decrease in carboxyterminal
phosphorylation staining. Loss of P-Smad2C remarkably correlated with depth of tumor infiltration and poor differentiation
of cancer cells in patients with gastric cancer. No correlation was detectable between P-Smad3C and clinicopathologic
characteristics of gastric adenocarcinoma. However, co-staining analysis revealed that P-Smad3C co-localised with a-SMA
and collagen I in gastric cancer cells, indicating a potential link between P-Smad3C and epithelial-to-mesenchymal transition
of cancer. Real time PCR demonstrated reduced mRNA expression of Smad2 in gastric cancer when compared with
surrounding non-tumor tissue in 15/16 patients.
Conclusions: Loss of P-Smad2C tightly correlated with cancer invasion and poor differentiation in gastric cancer. Contrary to
colorectal and hepatocellular carcinoma, canonical carboxy-terminal phosphorylation, but not linker phosphorylation, of
Smad2 is critical for gastric cancer.
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Introduction
Gastric cancer is a leading cause of cancer-related death in the
world, ranking second in males and fourth in females in frequency
[1]. The pathogenesis of gastric cancer is associated with multiple
factors. Among these, dysregulation of signaling pathways related
to developmental processes, including transforming growth factor-
b (TGF-b), Wnt/b-catenin, hedgehog and Notch signaling, plays a
central role in development and progression of this cancer [2].
The TGF-b family of molecules, including TGF-b isoforms,
activins and bone morphogenetic proteins (BMPs), has important
functions in various physiological and pathophysiological process-
es, e.g. embryonic development, autoimmune diseases, fibrosis and
cancer [3,4]. TGF-b transduces its signals by stimulating
formation of heteromeric complexes of TGF-b type I (TGF-bRI)
and type II (TGF-bRII) serine/threonine kinase receptors.
Activated TGF-bRI propagates signaling by recruitment and
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Smad2 and Smad3). Phosphorylation of C-terminal serine residues
in R-Smads is a crucial step for canonical TGF-b signaling. The
two most C-terminal serine residues at serine 465/467 in Smad2
and serine 423/425 in Smad3 are phosphorylated, together with a
third non-phosphorylated serine residue, form an evolutionarily
conserved SSXS motif in all R-Smads [5,6]. Besides C-terminal
phosphorylation of Smad2/3 (P-Smad2C and P-Smad3C) by
TGF-bRI, other kinases, e.g. c-Jun N-terminal kinase (JNK) and
Ras-associated kinases, cause phosphorylation of R-Smads at
linker sites around serine 249/254 in Smad2 and serine 208/213
in Smad3 (P-Smad2L and P-Smad3L) [7,8]. Phosphorylated R-
Smads form a complex with common Smad (Co-Smad; Smad4 in
mammals) and shuttle into the nucleus for target gene transcrip-
tion [3]. Besides R-Smad and co-Smad, the third type of Smad
protein is inhibitor-Smad (I-Smad; Smad6 and Smad7). I-Smads
are transcriptionally induced by TGF-b, indicating a negative
feedback mechanism of this signaling pathway [4].
TGF-b plays a dual role in the progression of human cancer
[9,10]. In the early stages of cancer, TGF-b acts as a tumor
suppressor by inhibiting cellular proliferation or by promoting
cellular apoptosis. However, in the late stages, TGF-b supports
tumor progression such as tumor cell invasion, dissemination and
immune evasion [9]. In addition, TGF-b is well recognised as a
mediator of epithelial-to-mesenchymal transition (EMT) in cancer
[11]. Although perturbations of TGF-b/Smad signaling are
central to carcinogenesis in most of organs, its tumor promoting
outcome is highly context-dependent. For example, TGF-b
signaling is pivotal in the maintenance of cancer stem cell self-
renewal and tumorigenic activity in glioma and leukaemia,
whereas the effects of TGF-b signaling in breast cancer stem cell
are controversial [12]. One study showed that blocking TGF-b
pathway via a dominant negative TGF-bRII increases the size of
breast stem cell compartment and promotes tumorigenesis,
indicating a suppression of breast carcinogenesis of this cytokine
[13]. By contrast, Mani and colleagues found that TGF-b pathway
us critical in the maintenance of breast cancer stem cell-like
properties and tumorigenic activity via inducing EMT [14].
In gastric cancer, single-nucleotide polymorphisms (SNPs) of
TGF-b are associated with susceptibility to stage I and stage II of
gastric cancer [15,16]. The serum levels of TGF-b were reported
to significantly correlate with venous invasion in patients with
gastric cancer [17]. However, detailed mechanisms of TGF-b
signaling in gastric cancer progression are still unknown. In
addition, it remains unclear when and how TGF-b transforms
from a tumor suppressor into a tumor promoter during
carcinogenesis.
Recently, a shift in phosphorylation of Smad2/3 from C-
terminal to linker sites was demonstrated as a key event
determining biological function of TGF-b in cancer [18,19,20].
Previous studies based on 12 year follow-up demonstrated that
chronic HBV/HCV patients with P-Smad2/3L in liver tissues had
a higher risk of advancing to hepatocellular carcinoma (HCC)
than those with P-Smad2/3C [8,21]. Consistent with the findings
in HCC, similar observations were made in colorectal cancer
[7,22].
To examine the contribution of differential Smad phosphory-
lation towards carcinogenesis in gastric cancer, we investigated P-
Smad2/3C and P-Smad2/3L levels in 130 patients with gastric
adenocarcinoma by immunohistochemistry (IHC). We analyzed
potential correlations between different sites of phosphorylation of
R-Smads and invasion, lymph node metastasis, differentiation,
and stage of gastric cancer.
Results
Linker phosphorylation of Smad2/3 is not associated with
gastric cancer
In contrast to previous findings from colorectal cancer and
HCC [7,8,21,22], we did not detect significant P-Smad2L and/or
P-Smad3L positive staining in gastric tissues from patients with
gastric cancer. Only 18 out of 130 patients showed p-Smad3L
positive staining mainly in non-cancer cells. These results suggest
that linker phosphorylation in serine sites of Smad2/3 is not
critical in gastric cancer.
Different features of P-Smad2C and P-Smad3C levels in
gastric cancer
118 out of 130 gastric tissues showed P-Smad2C positive
staining, and 91 out of 130 gastric tissues were positive for P-
Smad3C staining respectively. Distinct from P-Smad2C positive
staining, which was only displaying in the nucleus of normal and
cancer cells (Fig. 1A), P-Smad3C positive staining was demon-
strated in the nucleus (59/130, Fig. 1B), at the membrane and/or
in the cytoplasm (73/130, Fig. 1C) of gastric cancer cells. In
addition, P-Smad3C was seen by positive staining in fibroblasts
surrounding cancer cells (81/130 and 91/130, Fig. 1D).
Reduced P-Smad2C remarkably correlates with tumor
depth (T) and differentiation of cancer (G) in patients
with gastric cancer
We measured P-Smad2C IHC staining not only in the tumor
but also in surrounding non-tumor tissues from 130 patients with
gastric cancer. P-Smad2C positive staining in either cancer or
normal cells inversely correlated with differentiation of gastric
cancer (both p,0.0001, Table 1). In addition, decreased P-
Smad2C IHC score in cancer cells correlated with tumor depth
(p,0.05, Table 1). P-Smad2C levels in normal tissue as well
showed a potential inverse correlation with cancer invasion in
these patients (p=0.07, Table 1). The P-Smad2C IHC score was
significantly decreased in cancer tissues compared with non-tumor
tissues in 77 out of 130 patients with gastric cancer. Moreover,
within the tumor tissues, cancer cells with poorly atypia showed
decreased P-Smad2C staining, when compared with well-differ-
entiated ones (Fig. 2). Kendall-tau correlation analysis revealed a
potential correlation between reduction of P-Smad2C staining and
the transition from normal to cancer cells in gastric cancer
(p=0.05, Table 2), suggesting that activation of Smad2 signaling
is a critical suppressor of tumor formation and progression.
P-Smad3C is frequently found in cancer associated
fibroblasts
P-Smad3C IHC score did not show a significant correlation
with T/N/G/S of gastric cancer samples (Table 1). However, P-
Smad3C positive staining often occurred in fibroblasts surround-
ing cancer cells in patients with gastric cancer (Fig. 1).
Cancer cells are of epithelial origin and do not express
mesenchymal markers, e.g. a-SMA and collagen I. If cancer cells
express mesenchymal markers, it is suggestive of epithelial-to-
mesenchymal transition (EMT) [11]. In the present study, we
found a-SMA positive staining in cancer cells in 54 of 130 patients
with gastric cancer (e.g. patient-1 in Fig. 3). To clarify the
Smad2 in Gastric Cancer
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correlation between p-Smad3C staining (cancer and surrounding
non-cancer tissue) and a-SMA positive staining in cancer cells.
Kendall-tau rank correlation coefficients between p-Smad3C IHC
scores in cancer/surrounding non-cancer tissue and a-SMA IHC
scores in cancer are 0.14 (p=0.08) and 20.09 (p=0.99),
respectively (Table 3). To confirm EMT in these patients, we
performed co-staining for SNAIL, another specific marker for
EMT, and collagen I/a-SMA in gastric tissues. Confocal
microscopy revealed co-localization of SNAIL and collagen I
(Fig. 4A)/a-SMA (Fig. 4B) in some gastric cancer cells. These a-
SMA positive gastric cancer cells as well displayed P-Smad3C
positive staining (Fig. 4C). Besides co-localization with a-SMA
positive gastric cancer cells, confocal microscopy revealed that P-
Smad3C co-localized with collagen I in gastric cancer cells
(Fig. 4D). Further, P-Smad3C positive staining co-localized with
a-SMA and collagen I not only in cancer cells, but also in
fibroblasts (Fig. 4C–4D). These results suggest that P-Smad3C
may contribute to EMT of gastric cancer in some patients.
Loss of total Smad2 and Smad3 expression in patients
with gastric cancer
Besides measuring P-Smad2 in gastric cancer, we used real-time
PCR to detect mRNA expression of Smad2 and Smad3 in gastric
cancer and surrounding non-tumor tissues from 16 patients. 15
and 12 patients respectively demonstrated decreased mRNA
expression of Smad2 and Smad3 in cancer tissues, when compared
Figure 1. Patterns of P-Smad2C (A) and P-Smad3C (B–D) IHC staining in gastric cancer. (B) P-Smad3 nuclear staining; (C) P-Smad3 membrane/
plasma staining; (D) P-Smad3 fibroblast staining.
doi:10.1371/journal.pone.0035684.g001
Table 1. Correlation between P-Smad2C/P-Smad3C/a-SMA positive cells and gastric cancer (n=130).
Size of tumor (T) Lymph nodes (N) Tumor differentiation (G) TNM stage (S)
tB p value tB p value tB p value tB p value
pS2C_cancer 20.16 0.02 20.08 0.25 20.29 ,.0001 20.12 0.07
pS2C_normal 20.13 0.07 20.10 0.16 20.30 ,.0001 20.12 0.09
pS3C_cancer 20.07 0.35 20.08 0.30 20.05 0.56 20.09 0.21
pS3C_normal 20.08 0.31 20.10 0.20 0.08 0.34 20.09 0.25
pS3C_matrix 0.05 0.53 0.05 0.49 0.06 0.47 0.04 0.58
a-SMA 20.03 0.66 20.04 0.58 0.00 0.96 20.04 0.52
Kendall-tau rank correlation coefficient.
doi:10.1371/journal.pone.0035684.t001
Smad2 in Gastric Cancer
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that not only activated Smad2 but also the mRNA expression of
total Smad2 is reduced during gastric carcinogenesis.
Discussion
In colorectal adenocarcinoma and HCC, a shift in phosphor-
ylation from carboxy-terminus to linker regions has been suggested
as a critical event associated with the switch of TGF-b from a
cancer suppressor to an oncogenic factor [8,18,19,20,21,22]. In
the present study, we examined this potential association in gastric
cancer. We did not detect significant P-Smad2L and P-Smad3L
levels in 130 patients with gastric cancer. 112 out of 130 patients
did not show P-Smad2L or P-Smad3L staining in gastric cancer
cells, suggesting that the proposed shift in phosphorylation of R-
Smad may not contribute to TGF-b mediated carcinogenesis in
this type of cancer. In contrast to P-Smad2/3L, both P-Smad2C
and P-Smad3C positive staining was detected in most patients with
gastric cancer. Kendall-tau rank correlation analysis revealed that
P-Smad2C IHC score inversely correlates with depth of tumor (T)
and differentiation of cancer (G).
The role of Smad2 during formation and progression of
different cancer type remains controversial. Consistent with the
current finding, previous studies on esophageal squamous cell
carcinoma, breast cancer and colorectal cancer demonstrated that
loss of Smad2 expression is correlated with tumor development
and poor prognosis [23,24,25,26]. Recently, Hoot and colleagues
Figure 2. Loss of P-Smad2C in gastric cancer cells. (A) Immune positivity of P-Smad2C was significantly decreased in cancer tissues (b) when
compared with surrounding normal tissues (a) in 77 out of 130 patients with gastric cancer. Representative pictures were taken from a patient with
signet-ring cell carcinoma. (B) In tumor tissues, cancer cells with poor atypia (e–h) showed decreased P-Smad2C staining compared to those with a
well-differentiated phenotype (a–d).
doi:10.1371/journal.pone.0035684.g002
Table 2. Correlation between P-Smad2C change (cancer cells
versus normal tissues) and differentiation of gastric cancer (G)
(n=130).
pS2C (tumor
vs.normal) Down (%)
No change
(%) Up (%) total
#G2 (n=36) 0,72 0,19 0,08 1,00
G3 (n=79) 0,58 0,28 0,14 1,00
G4 (n=14) 0,36 0,64 0,00 1,00
tB 0.16
p value 0.05
Kendall-tau rank correlation coefficient.
doi:10.1371/journal.pone.0035684.t002
Smad2 in Gastric Cancer
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patients with skin squamous cell carcinoma. Further, mice with
keratinocyte-specific Smad2 deletion displayed accelerated forma-
tion and malignant progression of chemically induced mouse skin
tumors compared with wild type mice [27]. However, in a study of
52 patients with glioma, a positive P-Smad2 IHC score was
reported to correlate with proliferation of gliomas and poor
prognosis [28]. Prior to the present study, Shinto and colleagues
measured P-Smad2C staining in 135 patients with gastric cancer.
They found that the P-Smad2C levels were higher in poorly-
differentiated cancer when compared with well-differentiated ones
[29]. It is not clear yet why there are completely opposing results
in gastric cancer.
In canonical TGF-b signaling, activated TGF-bRI usually
induces carboxy-terminal phosphorylation of both Smad2 and
Smad3. Activated Smad2 and Smad3 play different roles in cell
growth, differentiation and other biological functions [30]. In the
liver, Smad2 is critical in mediating hepatocyte growth and
differentiation, whereas Smad3 plays a key effect in the
morphological and functional maturation of hepatic stellate cells
[31,32]. In cancer, it is controversial whether disruption of the
Smad3 gene contributes towards tumorigenesis. Zhu reported that
Smad3-deficient mice develop colon carcinoma [33]. However,
other studies using Smad3-deficient mice suggested that the loss of
Smad3 alone is not sufficient to initiate tumorigenesis
[34,35,36,37]. In gastric cancer, Han found low levels of Smad3
in 3 out of 8 patients and in nine human gastric cancer cell lines
[38]. Introduction of a Smad3 vector into gastric cell lines restored
TGF-b responsiveness. Further, injection of Smad3-expressing
gastric cells into nude mice showed delayed tumorigenesis when
compared with controls, indicating a correlation of loss of Smad3
with carcinogenesis [38]. In the present study, we did not find a
significant correlation between P-Smad3C staining in gastric
cancer cells and cancer invasion, differentiation and stage. Distinct
from P-Smad2C, which is only expressed in nuclei of cells, P-
Smad3C positive staining is detectable in the nucleus, at the
membrane and in the cytoplasm of gastric cancer cells. The
biological relevance of different patterns of P-Smad3C staining in
cancer cells is currently still unknown.
EMT of cancer cells is a prerequisite for progressing to
advanced metastatic tumors [11]. It has been recognized that
TGF-b is a major player in EMT. Smad3, but not Smad2, is a key
mediator in TGF-b dependent EMT [39]. For instance, TGF-b
fails to induce EMT in primary tubular epithelial cells derived
from kidneys of Smad3-deficient mice [40]. Inhibition of TGF-b
signalling by Ki26894, a TGF-bRI inhibitor, decreased invasion
and EMT of scirrhous gastric cancer in vitro [41]. Our results show
that part of gastric cancer cells express EMT markers, e.g. Snail,
collagen I and a-SMA. Co-localization of P-Smad3C with a-
SMA/collagen I is found in a substantial subset of patients. In
addition, a-SMA positive staining in cancer cells has a potential
correlation with P-Smad3C IHC score of cancer cells, but not
surrounding non-cancer tissues. These results indicate that P-
Smad3C might play a role in EMT of gastric cancer.
In Summary, the present study suggests that Smad2 is an
important mediator to defend gastric cells from progressing
towards poorly differentiated cancer. According to our results,
Smad3 is not directly linked with characteristics of gastric cancer,
however, our data indicated that it may play a role in cancer
associated fibroblasts and EMT of gastric cancer cells.
Methods
Patients
Surgical specimens were examined from patients with primary
gastric cancer at the Department of General Surgery, the First
Affiliated Hospital, Medical School, Zhejiang University, China
from 2003 to 2009. Gastric tissue specimen was collected when
surgeries dissected the Gastric cancer. The collected tissues
included tumor and surrounding non-tumor areas (tissues at least
more than 5 cm far away from the tumor). A part of tissues were
fixed with in 4% formaldehyde and embedded in paraffin for
histology and IHC measurement. Remained fresh tissues were put
into liquid nitrogen immediately for mRNA measurement. A total
of 130 paired gastric tissues including cancer and surrounding
non-tumor tissues were enrolled. Pathological diagnosis and
classifications were estimated according to the tumor-node-
metastasis (TNM) classification advocated by the International
Union against Cancer (seventh edition) [42]. Basic characteristics
of the enrolled patients are shown in Table 4. The study protocol
conformed to the ethical guidelines of the Declaration of Helsinki
(1975). The study was approved by the ethics committee of the
First Affiliated Hospital, Medical School, Zhejiang University.
Written informed consents were obtained from all participants
involved in the study.
Antibodies
Rabbit polyclonal antibodies against P-Smad2C (ser 465/467),
P-Smad3C (ser 423/425), P-Smad2L (ser 250/255), and P-
Smad3L (ser 208/213) were described in previous studies
[43,44]. Mouse anti-human a-SMA (M0851), polyclonal anti-
SNAIL (ab-17732), and monoclonal anti-collagen I (C2456)
antibodies were purchased from DAKO, Abcam and Sigma
respectively.
Immunohistochemistry (IHC)
After reviewing the H&E-stained slides from 130 enrolled
patients with gastric cancer, representative paraffin blocks for each
patient were selected for section. The slides were deparaffinised in
xylene and rehydrated in a dilution series of graded ethanol to
distilled water. Antigen retrieval was performed by microwave
treatment in EDTA buffer (1 mMol, pH 8.0). The slides were then
treated with 3% H2O2 for 30 min at room temperature. After
washing with PBS three times, the slides were incubated with
Table 3. Correlation between P-Smad2C/P-Smad3C and a-
SMA positive cells in gastric cancer (n=130).
pS3C_cancer pS3C_normal
tB p value tB p value
a-SMA 0.14 0.08 20.09 0.99
Kendall-tau rank correlation coefficient.
doi:10.1371/journal.pone.0035684.t003
Figure 3. P-Smad3C nuclear staining demonstrates a positive correlation with a-SMA expression in gastric cancer cells, but not in
surrounding non-tumor tissues. Representative pictures from two patients with gastric cancer show a-SMA and P-Smad3C staining in cancer area
(tumor) and surrounding non-cancer tissues (non-tumor).
doi:10.1371/journal.pone.0035684.g003
Smad2 in Gastric Cancer
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(1:100), P-Smad2L (1:50), P-Smad3L (1:50), and a-SMA (1:200)
respectively at 4uC overnight. The next day, the slides were
washed with PBS three times. After washing, they were incubated
with EnVision peroxidase (Dako) -labeled anti-rabbit or anti-
mouse antibody for 1 h at room temperature. Peroxidase activity
was detected with diaminobenzidine (DAB). The slides were
counterstained with hematoxylin. Immunoreactivity was visualized
under light microscopy.
For semiquantitative analysis, the stained tissue sections were
assessed at a 4-point scale as follows: positive cell counts, grades 0–
3 (0, no positive cells; 1, ,25% positive cells; 2, 25%–50% positive
cells; 3, .50% positive cells); intensity of positive staining, grades
1–3 (1, weak positive staining, usually yellow; 2, strong positive
Figure 4. Gastric cancer cells express EMT markers, including Snail, collagen I and a-SMA. Confocal microscopy analysis demonstrates co-
localization of Snail and collagen I (A)/a-SMA (B) in a representative patient with gastric cancer. The same patient in addition displays co-localization
of P-Smad3C and collagen I (C)/a-SMA (D) in gastric cancer.
doi:10.1371/journal.pone.0035684.g004
Figure 5. Real-time PCR was performed to determine mRNA expression of Smad2 (A) and Smad3 (B) in 16 gastric cancer tissues and surrounding
non-tumor tissues (No. 1–5: middle differentiated cancer; No. 6–13: poorly differentiated cancer and No. 14–16: signet-ring cell cancer).
doi:10.1371/journal.pone.0035684.g005
Smad2 in Gastric Cancer
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deep brown to black). The final immune staining score was
calculated as number6intensity.
Immunofluorescence staining
The slides were deparaffinised in xylene and rehydrated in
graded ethanol until distilled water. Then antigen retrieval was
performed by microwave treatment in EDTA buffer (1 mMol,
pH 8.0). The slides were then treated with 3%H2O2 for 30 min at
room temperature. After washing with PBS, both primary
antibodies, rabbit anti-P-Smad3C/Snail and mouse anti-a-
SMA/collagen I, were applied at 4uC overnight. Then, secondary
antibodies, Alexa633-rabbit anti-mouse immunoglobulin G and
Alexa488-donkey anti-rabbit immunoglobulin G (Molecular
Probes/Invitrogen, Karlsruhe, Germany), were applied for
30 min at room temperature. Samples were mounted using
Dako-Cytomation Fluorescent Mounting Medium. The slides
were inspected and pictures were taken on a confocal microscope
(Leica, Heidelberg). Sections without primary antibodies were
used as negative controls.
Real time PCR
The total RNA was purified from gastric tissues with the High
Pure RNA isolation kit (Roche Diagnostic GmbH, Mannheim,
Germany) according to the manufacturer’s protocol, and the
concentration was measured spectrophotometrically. cDNA was
synthesized from 1 mg of RNA with the Transcriptor First Strand
cDNA synthesis kit (Roche Diagnostics). Quantitative real-time
PCR was performed with an ABIPrism 7700 sequence detection
system (Applied Biosystems) using a TaqMan universal PCR
master mix No AmpErase UNG (part no. 4324018). The
following gene expression assays were used: Smad2 (forward:
CAAACCAGGTCTCTTGATGG; reverse: GAGGCGGAAG-
TTCTGTTAGG), Smad3 (forward: GGAGAAATGGTGCGA-
GAAGG; reverse: GAAGGCGAACTCACACAGC) and pepti-
dylprolyl isomerase A (housekeeping gene; part. no. Mm-
02342429_g1). All reagents were purchased from Applied
Biosystems. Samples were run in triplicate under the following
conditions: initial denaturation for 2 minutes at 50uC and for
10 minutes at 95uC followed by 40 cycles of 15 s at 95uC and
1 minute at 60uC. The levels of gene expression in each sample
were determined with the comparative cycle threshold method.
Statistical Analysis
To evaluate association between selected immunohistological
markers and tumor parameters, Kendall-tau rank correlation
analysis was performed using SAS version 9.2 (Cary, NC, USA). A
p,0.05 was considered statistically significant.
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Table 4. Basic characteristics of 130 patients with gastric
cancer.
Number
Age
,60 69
$60 61
Sex
M8 8
F4 2
Location
Proximal end of stomach (1/3) 10
Gastric body (1/3) 22
Distal end of stomach (1/3) 59
More than 1/3 of the stomach involved 39
Depth of tumor
Tis 3
T1 19
T2 32
T3 60
T4 16
Lymph node metastasis (N)
No 47
N1 19
N2 29
N3 35
Tumor differentiation (G)
Well diff. 22
Moderate Diff. 32
Poorly diff. 60
Undiff. 16
TNM stage
03
Ia 16
Ib 13
IIa 27
IIb 6
IIIa 22
IIIb 27
IIIc 16
doi:10.1371/journal.pone.0035684.t004
Smad2 in Gastric Cancer
PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e356847. Matsuzaki K, Kitano C, Murata M, Sekimoto G, Yoshida K, et al. (2009)
Smad2 and Smad3 phosphorylated at both linker and COOH-terminal regions
transmit malignant TGF-beta signal in later stages of human colorectal cancer.
Cancer Res 69: 5321–5330.
8. Matsuzaki K, Murata M, Yoshida K, Sekimoto G, Uemura Y, et al. (2007)
Chronic inflammation associated with hepatitis C virus infection perturbs
hepatic transforming growth factor beta signaling, promoting cirrhosis and
hepatocellular carcinoma. Hepatology 46: 48–57.
9. Meulmeester E, Ten Dijke P (2011) The dynamic roles of TGF-beta in cancer.
J Pathol 223: 205–218.
10. Yang L, Moses HL (2008) Transforming growth factor beta: tumor suppressor
or promoter? Are host immune cells the answer? Cancer Res 68: 9107–9111.
11. Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition.
J Clin Invest 119: 1420–1428.
12. Ikushima H, Miyazono K (2010) TGFbeta signalling: a complex web in cancer
progression. Nat Rev Cancer 10: 415–424.
13. Tang B, Yoo N, Vu M, Mamura M, Nam JS, et al. (2007) Transforming growth
factor-beta can suppress tumorigenesis through effects on the putative cancer
stem or early progenitor cell and committed progeny in a breast cancer
xenograft model. Cancer Res 67: 8643–8652.
14. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, et al. (2008) The epithelial-
mesenchymal transition generates cells with properties of stem cells. Cell 133:
704–715.
15. Li X, Yue ZC, Zhang YY, Bai J, Meng XN, et al. (2008) Elevated serum level
and gene polymorphisms of TGF-beta1 in gastric cancer. J Clin Lab Anal 22:
164–171.
16. Zhang Y, Liu B, Jin M, Ni Q, Liang X, et al. (2009) Genetic polymorphisms of
transforming growth factor-beta1 and its receptors and colorectal cancer
susceptibility: a population-based case-control study in China. Cancer Lett 275:
102–108.
17. Lin Y, Kikuchi S, Obata Y, Yagyu K (2006) Serum levels of transforming
growth factor beta1 are significantly correlated with venous invasion in patients
with gastric cancer. J Gastroenterol Hepatol 21: 432–437.
18. Matsuzaki K (2011) Smad phosphoisoform signals in acute and chronic liver
injury: similarities and differences between epithelial and mesenchymal cells.
Cell Tissue Res.
19. Matsuzaki K (2011) Smad phosphoisoform signaling specificity: the right place
at the right time. Carcinogenesis 32: 1578–1588.
20. Matsuzaki K, Okazaki K (2006) Transforming growth factor-beta during
carcinogenesis: the shift from epithelial to mesenchymal signaling.
J Gastroenterol 41: 295–303.
21. Murata M, Matsuzaki K, Yoshida K, Sekimoto G, Tahashi Y, et al. (2009)
Hepatitis B virus X protein shifts human hepatic transforming growth factor
(TGF)-beta signaling from tumor suppression to oncogenesis in early chronic
hepatitis B. Hepatology 49: 1203–1217.
22. Yamagata H, Matsuzaki K, Mori S, Yoshida K, Tahashi Y, et al. (2005)
Acceleration of Smad2 and Smad3 phosphorylation via c-Jun NH(2)-terminal
kinase during human colorectal carcinogenesis. Cancer Res 65: 157–165.
23. Fukuchi M, Nakajima M, Miyazaki T, Masuda N, Osawa H, et al. (2006) Lack
of activated Smad2 in transforming growth factor-beta signaling is an
unfavorable prognostic factor in patients with esophageal squamous cell
carcinoma. J Surg Oncol 94: 51–56.
24. Petersen M, Pardali E, van der Horst G, Cheung H, van den Hoogen C, et al.
(2010) Smad2 and Smad3 have opposing roles in breast cancer bone metastasis
by differentially affecting tumor angiogenesis. Oncogene 29: 1351–1361.
25. Xie W, Mertens JC, Reiss DJ, Rimm DL, Camp RL, et al. (2002) Alterations of
Smad signaling in human breast carcinoma are associated with poor outcome: a
tissue microarray study. Cancer Res 62: 497–505.
26. Xie W, Rimm DL, Lin Y, Shih WJ, Reiss M (2003) Loss of Smad signaling in
human colorectal cancer is associated with advanced disease and poor prognosis.
Cancer J 9: 302–312.
27. Hoot KE, Oka M, Han G, Bottinger E, Zhang Q, et al. (2010) HGF
upregulation contributes to angiogenesis in mice with keratinocyte-specific
Smad2 deletion. J Clin Invest 120: 3606–3616.
28. Bruna A, Darken RS, Rojo F, Ocana A, Penuelas S, et al. (2007) High
TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes
cell proliferation depending on the methylation of the PDGF-B gene. Cancer
Cell 11: 147–160.
29. Shinto O, Yashiro M, Toyokawa T, Nishii T, Kaizaki R, et al. (2010)
Phosphorylated smad2 in advanced stage gastric carcinoma. BMC Cancer 10:
652.
30. Brown KA, Pietenpol JA, Moses HL (2007) A tale of two proteins: differential
roles and regulation of Smad2 and Smad3 in TGF-beta signaling. J Cell
Biochem 101: 9–33.
31. Ju W, Ogawa A, Heyer J, Nierhof D, Yu L, et al. (2006) Deletion of Smad2 in
mouse liver reveals novel functions in hepatocyte growth and differentiation.
Mol Cell Biol 26: 654–667.
32. Uemura M, Swenson ES, Gaca MD, Giordano FJ, Reiss M, et al. (2005) Smad2
and Smad3 Play Different Roles in Rat Hepatic Stellate Cell Function and
{alpha}-Smooth Muscle Actin Organization. Mol Biol Cell.
33. Zhu Y, Richardson JA, Parada LF, Graff JM (1998) Smad3 mutant mice
develop metastatic colorectal cancer. Cell 94: 703–714.
34. Datto MB, Frederick JP, Pan L, Borton AJ, Zhuang Y, et al. (1999) Targeted
disruption of Smad3 reveals an essential role in transforming growth factor beta-
mediated signal transduction. Mol Cell Biol 19: 2495–2504.
35. Maggio-Price L, Treuting P, Zeng W, Tsang M, Bielefeldt-Ohmann H, et al.
(2006) Helicobacter infection is required for inflammation and colon cancer in
SMAD3-deficient mice. Cancer Res 66: 828–838.
36. Sodir NM, Chen X, Park R, Nickel AE, Conti PS, et al. (2006) Smad3 deficiency
promotes tumorigenesis in the distal colon of ApcMin/+ mice. Cancer Res 66:
8430–8438.
37. Yang X, Letterio JJ, Lechleider RJ, Chen L, Hayman R, et al. (1999) Targeted
disruption of SMAD3 results in impaired mucosal immunity and diminished T
cell responsiveness to TGF-beta. EMBO J 18: 1280–1291.
38. Han SU, Kim HT, Seong DH, Kim YS, Park YS, et al. (2004) Loss of the
Smad3 expression increases susceptibility to tumorigenicity in human gastric
cancer. Oncogene 23: 1333–1341.
39. Kalluri R, Neilson EG (2003) Epithelial-mesenchymal transition and its
implications for fibrosis. J Clin Invest 112: 1776–1784.
40. Zavadil J, Cermak L, Soto-Nieves N, Bottinger EP (2004) Integration of TGF-
beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transi-
tion. EMBO J 23: 1155–1165.
41. Shinto O, Yashiro M, Kawajiri H, Shimizu K, Shimizu T, et al. (2010)
Inhibitory effect of a TGFbeta receptor type-I inhibitor, Ki26894, on
invasiveness of scirrhous gastric cancer cells. Br J Cancer 102: 844–851.
42. Warneke VS, Behrens HM, Hartmann JT, Held H, Becker T, et al. (2011)
Cohort Study Based on the Seventh Edition of the TNM Classification for
Gastric Cancer: Proposal of a New Staging System. J Clin Oncol 29:
2364–2371.
43. Furukawa F, Matsuzaki K, Mori S, Tahashi Y, Yoshida K, et al. (2003) p38
MAPK mediates fibrogenic signal through Smad3 phosphorylation in rat
myofibroblasts. Hepatology 38: 879–889.
44. Sekimoto G, Matsuzaki K, Yoshida K, Mori S, Murata M, et al. (2007)
Reversible Smad-dependent signaling between tumor suppression and onco-
genesis. Cancer Res 67: 5090–5096.
Smad2 in Gastric Cancer
PLoS ONE | www.plosone.org 9 April 2012 | Volume 7 | Issue 4 | e35684